Integrated Drug Discovery Services
Looking for a Seamless Drug Discovery Partner?
Bringing a new therapy from concept to clinical development is a complex journey. Many organizations work with multiple CROs for screening, mechanism studies, toxicology, and regulatory support. While this approach may seem practical, it often creates fragmented data, inconsistent methodologies, communication gaps, and delays in development timelines.
At ImmunitasBio, we simplify the process through our Integrated Drug Discovery Services, providing a single scientific partner to support your programme from Target Identification to IND-enabling studies. Whether you are developing monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), cell and gene therapies, CAR-T therapies, CAR-NK therapies, or small molecules, our multidisciplinary team works alongside you to accelerate development with confidence.
Why Choose an Integrated Drug Discovery Approach?
One of the biggest challenges in drug development is maintaining continuity across different stages of research. When multiple vendors are involved, every handoff introduces potential risks:
ImmunitasBio eliminates these challenges by offering a unified scientific framework, a single quality system, and a consistent data narrative that supports regulatory success and faster decision-making.
How Does Our Drug Discovery Workflow Work?
Target Identification & Validation :
Every successful therapeutic programme begins with selecting the right target.
Our scientists support:
Hit Identification :
Once the target is validated, we help identify promising candidates through advanced screening approaches.
Our capabilities include:
Lead Optimisation :
Not every hit becomes a successful drug candidate.
During lead optimisation, we generate deeper biological insights through:
Candidate Selection :
Selecting the right development candidate requires robust comparative data
Our team performs comprehensive evaluations across:
IND-Enabling Studies :
As your programme approaches clinical development, we provide the critical studies required for regulatory submissions
Our IND-enabling capabilities include:
Cell & Gene Therapy Development :
Our advanced cell and gene therapy research platform supports :
